USD 0.59
(-4.76%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -2.57 Million USD | -558.47% |
2022 | -391.73 Thousand USD | -87.39% |
2021 | -209.04 Thousand USD | -440.75% |
2020 | 61.34 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -12.96 USD | 100.0% |
2024 Q1 | -466.6 Thousand USD | 81.91% |
2023 Q3 | - USD | 100.0% |
2023 Q1 | -186.11 Thousand USD | 52.49% |
2023 FY | -2.57 Million USD | -558.47% |
2023 Q2 | -49.95 Thousand USD | 73.16% |
2023 Q4 | -2.57 Million USD | 0.0% |
2022 Q4 | -391.73 Thousand USD | 0.0% |
2022 FY | -391.73 Thousand USD | -87.39% |
2022 Q3 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2021 FY | -209.04 Thousand USD | -440.75% |
2020 FY | 61.34 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AIM ImmunoTech Inc. | 160 Thousand USD | 1712.136% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -931.767% |
Armata Pharmaceuticals, Inc. | -29.24 Million USD | 91.179% |
Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -263.811% |
Azitra, Inc. | 260.45 Thousand USD | 1090.366% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 447.163% |
Calidi Biotherapeutics, Inc. | -1.25 Million USD | -105.368% |
CEL-SCI Corporation | -3.95 Million USD | 34.836% |
iBio, Inc. | -1.02 Million USD | -151.651% |
Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 131.175% |
MAIA Biotechnology, Inc. | - USD | Infinity% |
Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 80.741% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -2062.218% |
NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 132.672% |
NanoViricides, Inc. | -759.01 Thousand USD | -239.838% |
Oragenics, Inc. | -15.45 Million USD | 83.308% |
BiomX Inc. | -1.22 Million USD | -110.05% |
BiomX Inc. | -1.22 Million USD | -110.05% |
Protalix BioTherapeutics, Inc. | 42.51 Million USD | 106.068% |
Palatin Technologies, Inc. | 4.39 Million USD | 158.724% |
Scorpius Holdings, Inc. | -2.21 Million USD | -16.378% |